FDA issued close to 30 warning letters to cosmetics firms in 2016 for unapproved drug claims as part of “a project for reviewing product labels and websites for drug claims related to anti-aging.” That initiative may be winding down, if it hasn’t already, but the agency is playing its cards close to its vest going into the new year.
Cosmetic skin-care marketers may be able to breathe easier in 2017, with FDA potentially shifting its focus away from anti-aging claims that identify products as unapproved drugs.
The agency issued upwards of 30 warning letters in 2016 to companies for excessive anti-aging claims related to skin diseases...